Last reviewed · How we verify
Standard treatment with saline infusion
Saline infusion replaces or maintains fluid and electrolyte balance by delivering isotonic sodium chloride solution intravenously.
Saline infusion replaces or maintains fluid and electrolyte balance by delivering isotonic sodium chloride solution intravenously. Used for Dehydration and hypovolemia, Perioperative fluid maintenance, Electrolyte imbalance correction.
At a glance
| Generic name | Standard treatment with saline infusion |
|---|---|
| Sponsor | University of Roma La Sapienza |
| Drug class | Intravenous fluid / electrolyte replacement |
| Modality | Small molecule |
| Therapeutic area | Supportive Care / General Medicine |
| Phase | FDA-approved |
Mechanism of action
Saline infusion is a standard supportive therapy that restores intravascular volume and corrects electrolyte imbalances. It is used across multiple clinical contexts including dehydration, perioperative fluid management, and as a vehicle for drug delivery. The mechanism is purely physiological rather than pharmacological.
Approved indications
- Dehydration and hypovolemia
- Perioperative fluid maintenance
- Electrolyte imbalance correction
- Vehicle for intravenous drug administration
Common side effects
- Hyperchloremic acidosis
- Fluid overload / pulmonary edema
- Hypokalemia
- Phlebitis at infusion site
Key clinical trials
- Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older (PHASE2)
- Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction (PHASE2)
- Ketamine Treatment of Youth Suicide Attempters (PHASE3)
- Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases (PHASE2)
- Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy (NA)
- Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) (PHASE1)
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: